European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Go back to European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 56.70 -1.43 (2.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.13 | 52 Week High | $77.12 | |||
| Open | $57.74 | 52 Week Low | $49.03 | |||
| Day High | $58.11 | P/E | 36.82 | |||
| Day Low | $56.49 | EPS | $1.54 | |||
| Volume | 9,312,883 | |||||
